Revenio Group invests in artificial intelligence by acquiring AI software company Thirona Retina from Dutch company Thirona | Placera
Summary
In accordance with the agreement concluded at the time and upon the fulfillment of certain conditions, Icare has acquired the remaining share capital of Thirona Retina for approximately EUR 4.8 million. The acquisition advances Revenio’s current growth strategy as part of its mission to improve the quality of ophthalmic diagnostics through innovative products and solutions. Thirona Retina’s leading RetCAD™ product uses artificial intelligence to screen fundus images for diseases, including diabetic retinopathy, age-related macular degeneration, and glaucoma. By combining our cutting-edge AI medical device, RetCAD™, with iCares extensive expertise in the ophthalmic domain, we are poised to provide access to better eyecare to large numbers of patients on a global scale. Thirona Retina’s product, RetCAD™, is MDR Class IIa certified AI-powered software that analyzes fundus color images for ocular diseases.